CRO services
To make gene delivery more specific, we build a novel AAV discovery system, named AAVneO. AAVneO® capsid discovery platform uses multiple capsid engineering approaches to systematically and rapidly optimize AAV capsids, includes peptide insertion, error-prone PCR, capsid shuffling, saturation mutagenesis, and others. AAVneO® platform aims to overcome the limitations of naturally occurring virus capsids by improving targeting ability, yields, immune evasion and manufacturability.
Based on AAVneO, we can supply multiple services include capsid library design (peptide insertion, error-prone PCR, capsid shuffling, saturation mutagenesis, and others), production, two round of screening with NGS. We can do select in vitro and in vivo. Please connect with our technical support for your screening needs.
| Highlight
*AAV screening from billion abundance random mutant AAV libraries based on AAV1-AAV13.
*Comprehensive AAV screening systems of cell, organoid, rodent and non-human primates (NHP).
*Advanced process development capabilities enable high yield of candidate AAVs.
*High quality and diversity of the library.
*The NGS data from the plasmid library show that the frequency of randomly inserted peptide sequences (sequencing counts) is essentially the same. The proportion of random peptide sequences with a frequency of less than 6 is over 99%, and the Skew Ration is 2.0 (Skew Ration < 10), indicating that the plasmid library has a high degree of uniformity.
* Skew Ratio is the ratio of the number of peptide sequences corresponding to the 90% cumulative distribution to the number of peptide sequences corresponding to the 10% cumulative distribution. This value can directly reflect the uniformity of the library, and it is generally considered that if the Skew Ratio ＜ 10, the library is uniformly qualified.
OBiO also provides different off-the-shelf AAV capsid libraries. Each variant in this library may have unique surface characteristics and infection efficiency, which can be used for efficient and precise gene delivery targeting different cells or tissues. Please contact us for more information.
AAV capsid discovery is the process of creating and screening capsid variants to identify vectors with improved biological or manufacturing properties.
A discovery program may seek higher target-cell transduction, greater tissue specificity, reduced off-target distribution, immune evasion, improved packaging efficiency or better cross-species performance.
An AAV capsid library is a diverse collection of capsid-gene variants constructed using methods such as peptide insertion, random mutagenesis, capsid shuffling or targeted amino-acid substitution.
The variants are packaged and screened under defined biological conditions to enrich capsids with desired properties.
OBiO can evaluate in vivo screening strategies in project-relevant animal models. The species, administration route, tissue collection, screening rounds and molecular readouts should be defined according to the intended therapeutic application.
Capsid sequences can be recovered from selected cells or tissues and analyzed through next-generation sequencing.
Candidate ranking may consider sequence enrichment, reproducibility, tissue distribution, DNA abundance, RNA expression and performance relative to benchmark capsids.
Request Now